merged_fda-journavx-suzetrigine-vertex-opioids.txt
<question_number>1</question_number>
<answer>N/A</answer>
<question_number>2</question_number>
<answer>N/A</answer>
<question_number>3</question_number>
<answer>N/A</answer>
<question_number>4</question_number>
<answer>N/A</answer>
<question_number>5</question_number>
<answer>0</answer>
<question_number>6</question_number>
<answer>N/A</answer>
<question_number>7</question_number>
<answer>N/A</answer>
<question_number>8</question_number>
<answer>N/A</answer>
<question_number>9</question_number>
<answer>N/A</answer>
<question_number>10</question_number>
<answer>N/A</answer>
<question_number>11</question_number>
<answer>lumbosacral radiculopathy</answer>
<question_number>12</question_number>
<answer>2000</answer>
<question_number>13</question_number>
<answer>Nav1.7 and Nav1.8</answer>
<question_number>14</question_number>
<answer>$30.90+</answer>
<question_number>15</question_number>
<answer>2004</answer>
<question_number>16</question_number>
<answer>N/A</answer>
<question_number>17</question_number>
<answer>Nausea and drowsiness</answer>
<question_number>18</question_number>
<answer>0.2125%</answer>
<question_number>19</question_number>
<answer>Diabetic neuropathy</answer>
